Europe Vascular Graft Market size surpassed USD 618.7 million in 2020 and is anticipated to register a growth rate of 5.7% between 2021 and 2027.
Significant increase in number of conventional graft failures has given rise to technological advancements. For instance, Medtronic received CE Mark for its Endurant II/IIs stent graft system to treat abdominal aortic aneurysm (AAA). It is an efficient and safe endovascular abdominal aortic aneurysm (AAA) system developed for patients with complex aneurysms and short aortic neck length. Also, companies are developing vascular grafts that mimic human vessels that are hemocampatible, biocompatible and thrombus resistant. Thus, companies focusing on various product development will significantly contribute to the market growth.
Get more details on this report - Request Free Sample PDF
Endovascular aneurysm repair segment revenue was more than USD 260 million in 2020. Endovascular aneurysm repair is a minimally invasive grafting method intended for treatment of abdominal aortic aneurysms. The demand for endovascular aneurysm repair will be high in the upcoming future owing to cost-effectiveness, reduced hospital stays and growing adoption rate of minimally invasive surgical procedures. Thus, increasing demand for endovascular aneurysm repair across the region will propel the market demand.
Polyester grafts segment will expand at 6.1% CAGR during the forecast period. Recent advancements in polyester graft have enabled its rapid adoption and thus driving the segmental growth. For instance, combination of polyester grafts with collagen for development of biosynthetic grafts has provided better tensile strength and reduces chances of graft rejection. Thus, advancements in the polyester graft will spur the industry growth. Moreover, high demand of polyester grafts due to its associated advantages such as longer lifespan and blood compatibility will augment the segment size.
Hospitals segment accounted for 62.1% market share in 2020. Hospitals provide wide array of treatments for cardiothoracic surgery and hemodialysis procedures to patients suffering from complex medical conditions. This will increase the vascular graft product adoption rate. Also, increasing admission in hospital settings for various procedures will contribute to the segmental growth over the future. In addition, new clinical trials conducted in multi-specialty hospitals will provide opportunities to the patients to explore new experimental therapies.
UK vascular graft market size crossed USD 151.6 million in 2020 and is predicted to show growth of 6.9% till 2027. Growing geriatric population across the country is the major factor driving the demand for vascular grafts. For instance, according to World Health Organization (WHO) estimates, more than 5.5 million people aged 65 and above in UK by 2020. Moreover, development of minimally invasive endovascular aneurysm repair will further lead to escalated demand for procedure among elderly people. This will enable various healthcare professionals to opt for vascular graft products for procedures.
Key market players across Europe are Becton Dickinson (C.R. Bard), B. Braun Melsungen, Cook Medical, Endologix, Getinge AB, LeMaitre Vascular, Medtronic, among others.
Industry participants undertake various strategies such as mergers, collaborations, acquisitions, and geographic expansions to strengthen their market share. For instance, in March 2020, CryoLife, Inc. received CE Mark for the E-vita Open NEO, a hybrid stent graft system for the treatment of aortic arch disease. This strategy enabled company to add value to its existing portfolio as well as outreach to untapped economies.